| Pathological findings of COVID-19 associated with acute respiratory distress syndrome Z Xu, L Shi, Y Wang, J Zhang, L Huang, C Zhang, S Liu, P Zhao, H Liu, ... The Lancet respiratory medicine 8 (4), 420-422, 2020 | 10604 | 2020 |
| Liver injury in COVID-19: management and challenges C Zhang, L Shi, FS Wang The lancet Gastroenterology & hepatology 5 (5), 428-430, 2020 | 2264 | 2020 |
| Single-cell landscape of immunological responses in patients with COVID-19 JY Zhang, XM Wang, X Xing, Z Xu, C Zhang, JW Song, X Fan, P Xia, ... Nature immunology 21 (9), 1107-1118, 2020 | 560 | 2020 |
| Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping Y Xue, Y Zhou, T Wu, T Zhu, X Ji, YS Kwon, C Zhang, G Yeo, DL Black, ... Molecular cell 36 (6), 996-1006, 2009 | 519 | 2009 |
| Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis JW Song, SM Lam, X Fan, WJ Cao, SY Wang, H Tian, GH Chua, C Zhang, ... Cell metabolism 32 (2), 188-202. e5, 2020 | 452 | 2020 |
| Immunological and inflammatory profiles in mild and severe cases of COVID-19 JW Song, C Zhang, X Fan, FP Meng, Z Xu, P Xia, WJ Cao, T Yang, XP Dai, ... Nature communications 11 (1), 3410, 2020 | 394 | 2020 |
| What to do next to control the 2019-nCoV epidemic? FS Wang, C Zhang The Lancet 395 (10222), 391-393, 2020 | 311 | 2020 |
| Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial F Meng, R Xu, S Wang, Z Xu, C Zhang, Y Li, T Yang, L Shi, J Fu, T Jiang, ... Signal transduction and targeted therapy 5 (1), 172, 2020 | 307 | 2020 |
| Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial L Shi, H Huang, X Lu, X Yan, X Jiang, R Xu, S Wang, C Zhang, X Yuan, ... Signal transduction and targeted therapy 6 (1), 1-9, 2021 | 245 | 2021 |
| Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19) C Agrati, A Sacchi, V Bordoni, E Cimini, S Notari, G Grassi, R Casetti, ... Cell Death & Differentiation 27 (11), 3196-3207, 2020 | 241 | 2020 |
| A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19 SM Lam, C Zhang, Z Wang, Z Ni, S Zhang, S Yang, X Huang, L Mo, J Li, ... Nature metabolism 3 (7), 909-922, 2021 | 160 | 2021 |
| NKG2A is a NK cell exhaustion checkpoint for HCV persistence C Zhang, X Wang, S Li, T Twelkmeyer, W Wang, S Zhang, S Wang, ... Nature communications 10 (1), 1507, 2019 | 131 | 2019 |
| Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity C Zhang, J Feng, J Du, Z Zhuo, S Yang, W Zhang, W Wang, S Zhang, ... Cellular & Molecular Immunology 15 (11), 973-982, 2018 | 90 | 2018 |
| Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice J Chen, Y Zhao, C Zhang, H Chen, J Feng, X Chi, Y Pan, J Du, M Guo, ... Cell research 24 (9), 1050-1066, 2014 | 83 | 2014 |
| Mesenchymal stem cell therapy for severe COVID-19 L Shi, L Wang, R Xu, C Zhang, Y Xie, K Liu, T Li, W Hu, C Zhen, FS Wang Signal transduction and targeted therapy 6 (1), 339, 2021 | 81 | 2021 |
| NLRP3 inflammasome induces CD4+ T cell loss in chronically HIV-1–infected patients C Zhang, JW Song, HH Huang, X Fan, L Huang, JN Deng, B Tu, K Wang, ... The Journal of clinical investigation 131 (6), 2021 | 80 | 2021 |
| Human Mesenchymal Stem Cells Treatment for Severe COVID-19: 1-Year Follow-Up Results of a Randomized, Double-Blind, Placebo-Controlled Trial L Shi, X Yuan, WQ Yao, S Wang, C Zhang, B Zhang, J Song, L Huang, ... | 79 | 2021 |
| Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients C Zhang, J Li, Y Cheng, F Meng, JW Song, X Fan, H Fan, J Li, YL Fu, ... Gut 72 (1), 153-167, 2023 | 67 | 2023 |
| Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy—Achieving global … A Zumla, FS Wang, G Ippolito, N Petrosillo, C Agrati, EI Azhar, C Chang, ... International Journal of Infectious Diseases 96, 431-439, 2020 | 64 | 2020 |
| Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants E de Sousa, D Ligeiro, JR Lérias, C Zhang, C Agrati, M Osman, ... International Journal of Infectious Diseases 98, 454-459, 2020 | 62 | 2020 |
Professor Sir Alimuddin ZumlaUniversity College London在 ucl.ac.uk 的电子邮件经过验证
